4TVQ

CCM3 in complex with CCM2 LD-like motif


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.80 Å
  • R-Value Free: 0.277 
  • R-Value Work: 0.239 
  • R-Value Observed: 0.241 

wwPDB Validation 3D Report Full Report


This is version 1.3 of the entry. See complete history


Literature

CCM2-CCM3 interaction stabilizes their protein expression and permits endothelial network formation.

Draheim, K.M.Li, X.Zhang, R.Fisher, O.S.Villari, G.Boggon, T.J.Calderwood, D.A.

(2015) J Cell Biol 208: 987-1001

  • DOI: 10.1083/jcb.201407129
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • Mutations in the essential adaptor proteins CCM2 or CCM3 lead to cerebral cavernous malformations (CCM), vascular lesions that most frequently occur in the brain and are strongly associated with hemorrhagic stroke, seizures, and other neurological di ...

    Mutations in the essential adaptor proteins CCM2 or CCM3 lead to cerebral cavernous malformations (CCM), vascular lesions that most frequently occur in the brain and are strongly associated with hemorrhagic stroke, seizures, and other neurological disorders. CCM2 binds CCM3, but the molecular basis of this interaction, and its functional significance, have not been elucidated. Here, we used x-ray crystallography and structure-guided mutagenesis to show that an α-helical LD-like motif within CCM2 binds the highly conserved "HP1" pocket of the CCM3 focal adhesion targeting (FAT) homology domain. By knocking down CCM2 or CCM3 and rescuing with binding-deficient mutants, we establish that CCM2-CCM3 interactions protect CCM2 and CCM3 proteins from proteasomal degradation and show that both CCM2 and CCM3 are required for normal endothelial cell network formation. However, CCM3 expression in the absence of CCM2 is sufficient to support normal cell growth, revealing complex-independent roles for CCM3.


    Organizational Affiliation

    Department of Pharmacology and Department of Cell Biology, Yale University, New Haven, CT 06520 Department of Pharmacology and Department of Cell Biology, Yale University, New Haven, CT 06520 titus.boggon@yale.edu david.calderwood@yale.edu.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Cerebral cavernous malformations 3 protein
A, B, C, D
214Homo sapiensMutation(s): 0 
Gene Names: PDCD10CCM3TFAR15
Find proteins for Q9BUL8 (Homo sapiens)
Go to UniProtKB:  Q9BUL8
NIH Common Fund Data Resources
PHAROS  Q9BUL8
Protein Feature View
  • Reference Sequence
  • Find similar proteins by: Sequence   |   Structure
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Cerebral cavernous malformations 2 protein
E
16Homo sapiensMutation(s): 0 
Gene Names: CCM2C7orf22PP10187
Find proteins for Q9BSQ5 (Homo sapiens)
Go to UniProtKB:  Q9BSQ5
NIH Common Fund Data Resources
PHAROS  Q9BSQ5
Protein Feature View
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.80 Å
  • R-Value Free: 0.277 
  • R-Value Work: 0.239 
  • R-Value Observed: 0.241 
  • Space Group: P 21 21 21
  • Diffraction Data DOI: 10.15785/SBGRID/558 SBGrid
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 61.855α = 90
b = 113.552β = 90
c = 120.034γ = 90
Software Package:
Software NamePurpose
Cootmodel building
PHENIXrefinement
PHASERphasing
HKL-2000data reduction
HKL-2000data scaling

Structure Validation

View Full Validation Report



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS)United StatesR01NS085078
American Heart AssociationUnited States11POST7630017

Revision History 

  • Version 1.0: 2015-03-25
    Type: Initial release
  • Version 1.1: 2015-10-21
    Changes: Data collection, Database references
  • Version 1.2: 2017-09-20
    Changes: Author supporting evidence, Derived calculations
  • Version 1.3: 2019-12-18
    Changes: Author supporting evidence